Adalvo’s submission to the DCP for Cariprazine capsules is due in November 2025.
With this timing, we expect to be among the first companies ready for Day-1 launch in major markets.
Based on the reference brand, Reaglia®, Cariprazine is the only approved antipsychotic with proven superiority over a second-generation therapy, Risperidone.
Cariprazine expands Adalvo’s CNS pipeline with a targeted product that addresses unmet needs in schizophrenia treatment. Global sales of Cariprazine reached $4.5 million in 2024, with a 3Y CAGR of 32%, revealing a steady growth potential for this generic therapy.
To explore licensing or partnership opportunities, contact the Adalvo Business Development team.